Timeline

Scrub through the years. Approvals, landmark trials, cancer history events, and roadmap eras appear as they stood in the chosen year, all derived from dated records in the corpus.

2026

1940195019601970198019902000201020202030

305

products approved to date

367

landmark trials reported to date

roadmap eras active

This year: 2026

Approvals (34)

Acalabrutinib · US · Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)
ArteraAI Breast · US · Risk stratification in early-stage HR+/HER2- invasive breast cancer
Atezolizumab · US · Adjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy
Belzutifan · US · Adjuvant clear-cell RCC with pembrolizumab
Camizestrant · US · HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)
Capivasertib · US · PTEN-deficient metastatic prostate cancer with abiraterone
Daratumumab · US · With teclistamab after ≥1 line (MajesTEC-3); high-risk smouldering myeloma (AQUILA)
Daraxonrasib · US · Metastatic pancreatic cancer (previously treated)
Datopotamab deruxtecan · US · First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible
Decitabine + cedazuridine (oral) · US · Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)
Durvalumab · US · High-risk NMIBC with BCG
Encorafenib · US · First-line BRAF V600E mCRC with cetuximab and chemotherapy
Gedatolisib · US · HR+/HER2- advanced breast cancer after CDK4/6 inhibitor (July 2026)
Isatuximab · US · Subcutaneous formulation (Sarclisa Escena)
Lutetium-177 vipivotide tetraxetan · US · Label expansion (July 2026)
Nivolumab · US · Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
Optune / Optune Pax (TTFields) · US · Locally advanced pancreatic cancer with chemotherapy
Palbociclib · US · HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy
Pembrolizumab · US · Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
Piflufolastat F-18 / Pylarify TruVu · US · Pylarify TruVu formulation
Pivekimab sunirine · US · Blastic plasmacytoid dendritic cell neoplasm
Relacorilant · US · Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
Rusfertide · US · Erythrocytosis in adults with polycythaemia vera
Sacituzumab govitecan · US · First-line metastatic TNBC: monotherapy (PD-1 ineligible) or with pembrolizumab (PD-L1 CPS ≥10)
Selpercatinib · US · Label update (July 2026)
Sonrotoclax · US · Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)
Teclistamab · US · Relapsed/refractory myeloma after ≥1 prior therapy
Tovorafenib · EU · Relapsed/refractory paediatric low-grade glioma (conditional)
Trastuzumab deruxtecan · US · Early-stage HER2+ breast cancer (neoadjuvant and post-neoadjuvant)
Vepdegestrant · US · ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy
Vusolimogene oderparepvec · US · Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)
Zenocutuzumab · US · NRG1-fusion cholangiocarcinoma
Zidesamtinib · US · ROS1+ NSCLC (July 2026)
Zongertinib · US · First-line HER2-mutant non-squamous NSCLC

Trials reported (21)

AMPLIFY-7P Negative · Pancreatic ductal adenocarcinoma
ASCERTAIN-V Positive · Acute myeloid leukaemia
AZUR-1 Positive · Colorectal cancer
BL-B01D1-307 Positive · Triple-negative breast cancer
CLARITY-Gastric 01 Positive · Gastric & gastro-oesophageal junction cancer
DREAM3R Negative · Mesothelioma
EMERALD-3 Positive · Hepatocellular carcinoma
EPCORE DLBCL-1 Mixed · Diffuse large B-cell lymphoma
Fianlimab + cemiplimab phase 3 (first-line melanoma) Negative · Melanoma
FOURLIGHT-1 Positive · HR-positive / HER2-negative breast cancer
HARMONi-3 Mixed · Non-small-cell lung cancer
HERIZON-GEA-01 Positive · Gastric & gastro-oesophageal junction cancer, Oesophageal cancer
INSIGHT Positive · Sarcomas
INTerpath-001 (V940-001) Positive · Melanoma
Krascendo 1 Positive · Non-small-cell lung cancer
LITESPARK-012 Negative · Renal cell carcinoma
LITESPARK-022 Positive · Renal cell carcinoma
PANKU-Esophagus01 (BL-B01D1-305) Positive · Oesophageal cancer
persevERA Negative · HR-positive / HER2-negative breast cancer
RASolute 302 Positive · Pancreatic ductal adenocarcinoma
XPORT-EC-042 / ENGOT-EN20 / GOG-3083 Negative · Endometrial cancer

History events (45)

Acute lymphoblastic leukaemia: Subcutaneous blinatumomab and Interfant-21 progress — Subcutaneous blinatumomab trials (including the first in mixed-phenotype leukaemia) aim to replace continuous infusion; infant trials integrate blinatumomab.Blinatumomab Interfant-06
Acute myeloid leukaemia: First all-oral AML regimen — Decitabine-cedazuridine + venetoclax approved 13 May 2026 (ASCERTAIN-V, CR 41.6%).Decitabine + cedazuridine (oral)ASCERTAIN-V
Biliary tract cancer: Zenocutuzumab approved for NRG1-fusion cholangiocarcinoma; HERIZON-BTC-302 enrollingZenocutuzumab HERIZON-BTC-302
Bladder & urothelial cancer: IMvigor011: ctDNA-guided atezolizumab approvedIMvigor011
Bladder & urothelial cancer: IMvigor011 ctDNA-guided atezolizumab and POTOMAC durvalumab + BCG approved; cretostimogene BLA under wayIMvigor011 POTOMAC Cretostimogene grenadenorepvec
Blastic plasmacytoid dendritic cell neoplasm: Pivekimab sunirine approved — CD123 ADC (CADENZA), FDA May 2026.Pivekimab sunirine
Cervical cancer: World Health Assembly calls for accountable elimination systems; sac-TMT and TIL trials in recurrent diseaseSacituzumab tirumotecan Lifileucel
Chronic lymphocytic leukaemia: Acalabrutinib frontline label expanded
Chronic lymphocytic leukaemia: First US all-oral fixed-duration regimen; sonrotoclax US approval (MCL); BTK degrader phase 3 — Acalabrutinib-venetoclax approved 19 February; sonrotoclax accelerated approval 13 May; CaDAnCe-304 and CELESTIAL-TNCLL enrolling.Acalabrutinib AMPLIFY Sonrotoclax BGB-16673 CaDAnCe-304
Colorectal cancer: BREAKWATER full approval; first-line BRAF targeted therapyEncorafenib
Colorectal cancer: BREAKWATER FOLFIRI cohort and full approval; AZUR-1 priority review; T-DXd and RAS(ON) inhibitors advanceBREAKWATER AZUR-1 Daraxonrasib
Diffuse large B-cell lymphoma: frontMIND published in Lancet; EPCORE DLBCL-1 misses OS; frontline bispecific data (EPCORE DLBCL-2) at EHAfrontMIND EPCORE DLBCL-1 EPCORE DLBCL-2
Endometrial cancer: Selinexor maintenance fails (XPORT-EC-042) — Post-hoc TP53-wild-type subgroup hypothesis not confirmed.XPORT-EC-042 / ENGOT-EN20 / GOG-3083 Selinexor
Follicular lymphoma: Tazemetostat withdrawn worldwide — Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.Tazemetostat
Gastric & gastro-oesophageal junction cancer: HERIZON-GEA-01: zanidatamab beats trastuzumab; CLARITY-Gastric 01: first CLDN18.2 ADC with OS benefitHERIZON-GEA-01 CLARITY-Gastric 01
Glioma & glioblastoma: ASCO 2026: NeoVax personalised vaccine immune responses; multi-target CAR-T; tovorafenib EU approvalTovorafenib CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)Neoadjuvant immunotherapy with surgical window for glioblastoma
Hepatocellular carcinoma: EMERALD-3 positive for PFS; LEAP-012 final OS HR 0.98; IMbrave050 update negative; third camrelizumab-rivoceranib CRL (23 July)EMERALD-3 LEAP-012 IMbrave050 CARES-310
HER2-positive breast cancer: T-DXd approved in early-stage diseaseDESTINY-Breast11
HER2-positive breast cancer: T-DXd approved neoadjuvant and post-neoadjuvant; palbociclib maintenance for HR+/HER2+ (PATINA)DESTINY-Breast11 DESTINY-Breast05 Palbociclib
Hodgkin lymphoma: Nivolumab-AVD approved first lineNivolumab
Hodgkin lymphoma: Nivolumab-AVD approved by FDA (20 March) for ages 12+; HD21 5-year data confirm BrECADDSWOG S1826 Nivolumab GHSG HD21
HR-positive / HER2-negative breast cancer: First PROTAC (vepdegestrant) and gedatolisib approvedVepdegestrant Gedatolisib
HR-positive / HER2-negative breast cancer: First PROTAC (vepdegestrant), gedatolisib, and the first ctDNA-triggered switch (camizestrant) approved; persevERA fails upfrontVepdegestrant VERITAC-2 Gedatolisib Camizestrant SERENA-6 persevERA
Mantle cell lymphoma: Sonrotoclax approved for relapsed MCLSonrotoclax
Melanoma: Intismeran phase 3 positive; RP1 approvedINTerpath-001 (V940-001)Vusolimogene oderparepvec
Melanoma: Intismeran autogene phase 3 positive; RP1 approved with nivolumab; fianlimab-cemiplimab phase 3 misses; brenetafusp phase 3 enrollingINTerpath-001 (V940-001)Intismeran autogene Vusolimogene oderparepvec Fianlimab + cemiplimab phase 3 (first-line melanoma)PRISM-MEL-301
Mesothelioma: DREAM3R stopped early; PRMT5 inhibitors and mesothelin cell therapies advanceDREAM3R PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma Regionally delivered mesothelin CAR-T with PD-1 blockade
Multiple myeloma: Teclistamab after ≥1 line; isatuximab SC
Multiple myeloma: Teclistamab + daratumumab approved after ≥1 line (MajesTEC-3); isatuximab subcutaneous; anito-cel BLA accepted (PDUFA December)MajesTEC-3 Isatuximab Anitocabtagene autoleucel
Myeloproliferative neoplasms: Rusfertide approved for PV — VERIFY: hepcidin mimetic controls erythrocytosis without phlebotomy; FDA approval August 2026.Rusfertide
Neuroblastoma: ANBL1531 MIBG randomisation maturing; ALK arm reportsCOG ANBL1531
Neuroendocrine tumours: FDA accepts 177Lu-edotreotide NDA (PDUFA 28 August); ACTION-1 dosimetry published; pancreatic subgroup of COMPETE at ENETS177Lu-edotreotide ACTION-1
Non-small-cell lung cancer: Zongertinib first line; zidesamtinib (ROS1) approved; divarasib beats first-generation KRAS inhibitors; neladalkib and ivonescimab under FDA reviewZongertinib Zidesamtinib Krascendo 1 Neladalkib ALKOVE-1 HARMONi-3
Oesophageal cancer: Iza-bren phase 3 positiveBL-B01D1-307
Oesophageal cancer: PANKU-Esophagus01: iza-bren improves OS in second-line ESCC; HERIZON-GEA-01 for HER2+ GEJ; CheckMate 648 five-year dataPANKU-Esophagus01 (BL-B01D1-305)HERIZON-GEA-01 CheckMate 648
Ovarian cancer: Relacorilant and pembrolizumab approved in platinum-resistant diseaseRelacorilant
Ovarian cancer: Relacorilant and pembrolizumab approved in platinum-resistant disease — First immunotherapy approval in ovarian cancer (February 2026).Relacorilant Pembrolizumab KEYNOTE-B96 / ENGOT-ov65
Pancreatic ductal adenocarcinoma: Optune Pax approved; daraxonrasib phase 3 enrolledOptune / Optune Pax (TTFields)Daraxonrasib
Pancreatic ductal adenocarcinoma: RASolute 302: daraxonrasib OS 13.2 vs 6.7 months (HR 0.40) — ASCO plenary and NEJM; Optune Pax approved; zoldonrasib combinations reported; AMPLIFY-7P vaccine misses.RASolute 302 Optune / Optune Pax (TTFields)Zoldonrasib AMPLIFY-7P
Prostate cancer: Pluvicto approved in metastatic hormone-sensitive disease (31 July); capivasertib + abiraterone approved for PTEN-deficient diseasePSMAddition Lutetium-177 vipivotide tetraxetan CAPItello-281 Capivasertib
Renal cell carcinoma: LITESPARK-022 positive and approved (adjuvant belzutifan + pembrolizumab); LITESPARK-012 first-line triplet falls shortLITESPARK-022 LITESPARK-012
Sarcomas: Tazemetostat withdrawn worldwide (9 March); afami-cel full approval and age ≥12 (June); INSIGHT positiveAfamitresgene autoleucel INSIGHT EZH2
Small-cell lung cancer: Phase 3 readouts pending for I-DXd and tarlatamab maintenanceIDeate-Lung02 DeLLphi-305
Thyroid cancer: Selpercatinib label update (July 2026)Selpercatinib
Triple-negative breast cancer: Bispecific ADC succeeds; first-line ADC approvals — Iza-bren phase 3 positive (Feb 2026); FDA approves Dato-DXd and sacituzumab govitecan first line (Q2 2026).BL-B01D1-307 Datopotamab deruxtecan Sacituzumab govitecan

Roadmap eras active (31)

Standard of care as of 2026 derived

Best effort: for each cancer, the most recent dated history event at or before 2026 that references products or technologies. Not a guideline; see each cancer page for the current standard of care.

Acute lymphoblastic leukaemia (2026) · Subcutaneous blinatumomab and Interfant-21 progress
Blinatumomab Interfant-06
Acute myeloid leukaemia (2026) · First all-oral AML regimen
Decitabine + cedazuridine (oral)ASCERTAIN-V
Adrenocortical carcinoma (2023) · ADIUVO: no benefit of adjuvant mitotane in low-risk disease
Mitotane
Anal cancer (2024) · POD1UM-303: retifanlimab + chemotherapy improves PFS/OS
Retifanlimab
Appendiceal cancer and pseudomyxoma peritonei (2024) · Randomised trial: no benefit of systemic chemotherapy in low-grade mucinous carcinoma peritonei
FOLFOX (5-FU, leucovorin, oxaliplatin)
Basal cell carcinoma (2021) · Cemiplimab approved after hedgehog-inhibitor failure
Cemiplimab
Biliary tract cancer (2026) · Zenocutuzumab approved for NRG1-fusion cholangiocarcinoma; HERIZON-BTC-302 enrolling
Zenocutuzumab HERIZON-BTC-302
Bladder & urothelial cancer (2026) · IMvigor011 ctDNA-guided atezolizumab and POTOMAC durvalumab + BCG approved; cretostimogene BLA under way
IMvigor011 POTOMAC Cretostimogene grenadenorepvec
Blastic plasmacytoid dendritic cell neoplasm (2026) · Pivekimab sunirine approved
Pivekimab sunirine
Cancer of unknown primary (2024) · CUPISCO: molecularly guided therapy improves PFS (Lancet)
Comprehensive genomic profiling
Cervical cancer (2026) · World Health Assembly calls for accountable elimination systems; sac-TMT and TIL trials in recurrent disease
Sacituzumab tirumotecan Lifileucel
Chronic lymphocytic leukaemia (2026) · First US all-oral fixed-duration regimen; sonrotoclax US approval (MCL); BTK degrader phase 3
Acalabrutinib AMPLIFY Sonrotoclax BGB-16673 CaDAnCe-304
Chronic myeloid leukaemia (2024) · Asciminib first line
Asciminib
Colorectal cancer (2026) · BREAKWATER FOLFIRI cohort and full approval; AZUR-1 priority review; T-DXd and RAS(ON) inhibitors advance
BREAKWATER AZUR-1 Daraxonrasib
Cutaneous squamous cell carcinoma (2025) · C-POST: adjuvant cemiplimab reduces recurrence
Cemiplimab
Diffuse large B-cell lymphoma (2026) · frontMIND published in Lancet; EPCORE DLBCL-1 misses OS; frontline bispecific data (EPCORE DLBCL-2) at EHA
frontMIND EPCORE DLBCL-1 EPCORE DLBCL-2
Endometrial cancer (2026) · Selinexor maintenance fails (XPORT-EC-042)
XPORT-EC-042 / ENGOT-EN20 / GOG-3083 Selinexor
Ewing sarcoma (2022) · rEECur: high-dose ifosfamide best of four relapse regimens
Ifosfamide
Follicular lymphoma (2026) · Tazemetostat withdrawn worldwide
Tazemetostat
Gastric & gastro-oesophageal junction cancer (2026) · HERIZON-GEA-01: zanidatamab beats trastuzumab; CLARITY-Gastric 01: first CLDN18.2 ADC with OS benefit
HERIZON-GEA-01 CLARITY-Gastric 01
Gastrointestinal stromal tumour (2022) · INTRIGUE: ctDNA genotype predicts ripretinib vs sunitinib benefit
Ripretinib Sunitinib
Gestational trophoblastic neoplasia (2020) · TROPHIMMUN: avelumab in methotrexate-resistant low-risk GTN
Avelumab
Glioma & glioblastoma (2026) · ASCO 2026: NeoVax personalised vaccine immune responses; multi-target CAR-T; tovorafenib EU approval
Tovorafenib CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)Neoadjuvant immunotherapy with surgical window for glioblastoma
Hairy cell leukaemia (2021) · Vemurafenib + rituximab: chemo-free durable remissions (NEJM)
Vemurafenib Rituximab
Head and neck squamous cell carcinoma (2025) · KEYNOTE-689 perioperative pembrolizumab approved; NRG-HN005 de-escalation fails; petosemtamab and ficerafusp alfa phase 3 trials
KEYNOTE-689 NRG-HN002 & NRG-HN005 (HPV+ de-escalation)LiGeR-HN1 FORTIFI-HN01
Hepatoblastoma (2018) · SIOPEL-6: sodium thiosulfate halves cisplatin hearing loss (NEJM)
Sodium thiosulfate (otoprotectant)
Hepatocellular carcinoma (2026) · EMERALD-3 positive for PFS; LEAP-012 final OS HR 0.98; IMbrave050 update negative; third camrelizumab-rivoceranib CRL (23 July)
EMERALD-3 LEAP-012 IMbrave050 CARES-310
HER2-positive breast cancer (2026) · T-DXd approved neoadjuvant and post-neoadjuvant; palbociclib maintenance for HR+/HER2+ (PATINA)
DESTINY-Breast11 DESTINY-Breast05 Palbociclib
Hodgkin lymphoma (2026) · Nivolumab-AVD approved by FDA (20 March) for ages 12+; HD21 5-year data confirm BrECADD
SWOG S1826 Nivolumab GHSG HD21
HR-positive / HER2-negative breast cancer (2026) · First PROTAC (vepdegestrant), gedatolisib, and the first ctDNA-triggered switch (camizestrant) approved; persevERA fails upfront
Vepdegestrant VERITAC-2 Gedatolisib Camizestrant SERENA-6 persevERA
Kaposi sarcoma (2020) · ACTG A5263: paclitaxel superior to oral etoposide and bleomycin-vincristine in Africa (Lancet)
Paclitaxel / nab-paclitaxel Bleomycin
Mantle cell lymphoma (2026) · Sonrotoclax approved for relapsed MCL
Sonrotoclax
Medulloblastoma (2017) · Proton CSI: equivalent control, fewer toxicities (Yock, Lancet Oncol)
Proton therapy
Melanoma (2026) · Intismeran autogene phase 3 positive; RP1 approved with nivolumab; fianlimab-cemiplimab phase 3 misses; brenetafusp phase 3 enrolling
INTerpath-001 (V940-001)Intismeran autogene Vusolimogene oderparepvec Fianlimab + cemiplimab phase 3 (first-line melanoma)PRISM-MEL-301
Merkel cell carcinoma (2023) · Retifanlimab approved; ADMEC-O adjuvant nivolumab positive
Retifanlimab Nivolumab
Mesothelioma (2026) · DREAM3R stopped early; PRMT5 inhibitors and mesothelin cell therapies advance
DREAM3R PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma Regionally delivered mesothelin CAR-T with PD-1 blockade
Multiple myeloma (2026) · Teclistamab + daratumumab approved after ≥1 line (MajesTEC-3); isatuximab subcutaneous; anito-cel BLA accepted (PDUFA December)
MajesTEC-3 Isatuximab Anitocabtagene autoleucel
Myelodysplastic syndromes / neoplasms (2024) · Imetelstat approved
Imetelstat
Myeloproliferative neoplasms (2026) · Rusfertide approved for PV
Rusfertide
Nasopharyngeal carcinoma (2025) · Penpulimab approved (FDA)
Penpulimab
Neuroblastoma (2026) · ANBL1531 MIBG randomisation maturing; ALK arm reports
COG ANBL1531
Neuroendocrine tumours (2026) · FDA accepts 177Lu-edotreotide NDA (PDUFA 28 August); ACTION-1 dosimetry published; pancreatic subgroup of COMPETE at ENETS
177Lu-edotreotide ACTION-1
Non-small-cell lung cancer (2026) · Zongertinib first line; zidesamtinib (ROS1) approved; divarasib beats first-generation KRAS inhibitors; neladalkib and ivonescimab under FDA review
Zongertinib Zidesamtinib Krascendo 1 Neladalkib ALKOVE-1 HARMONi-3
Oesophageal cancer (2026) · PANKU-Esophagus01: iza-bren improves OS in second-line ESCC; HERIZON-GEA-01 for HER2+ GEJ; CheckMate 648 five-year data
PANKU-Esophagus01 (BL-B01D1-305)HERIZON-GEA-01 CheckMate 648
Osteosarcoma (2019) · Regorafenib (SARC024, REGOBONE) and cabozantinib (CABONE) show activity at relapse
Regorafenib Cabozantinib
Ovarian cancer (2026) · Relacorilant and pembrolizumab approved in platinum-resistant disease
Relacorilant Pembrolizumab KEYNOTE-B96 / ENGOT-ov65
Pancreatic ductal adenocarcinoma (2026) · RASolute 302: daraxonrasib OS 13.2 vs 6.7 months (HR 0.40)
RASolute 302 Optune / Optune Pax (TTFields)Zoldonrasib AMPLIFY-7P
Peripheral T-cell lymphomas (2021) · Romidepsin US PTCL indication withdrawn
Romidepsin
Primary CNS lymphoma (2022) · IELSG32 7-year update confirms cures
Autologous stem cell transplant (high-dose therapy)
Prostate cancer (2026) · Pluvicto approved in metastatic hormone-sensitive disease (31 July); capivasertib + abiraterone approved for PTEN-deficient disease
PSMAddition Lutetium-177 vipivotide tetraxetan CAPItello-281 Capivasertib
Renal cell carcinoma (2026) · LITESPARK-022 positive and approved (adjuvant belzutifan + pembrolizumab); LITESPARK-012 first-line triplet falls short
LITESPARK-022 LITESPARK-012
Retinoblastoma (2017) · Aqueous humour as liquid biopsy (Berry)
Liquid biopsy (ctDNA)
Rhabdomyosarcoma (2024) · ARST1431: temsirolimus + chemotherapy improves EFS in intermediate risk
Temsirolimus
Salivary gland cancers (2019) · Trastuzumab-docetaxel in HER2+ salivary duct carcinoma (Takahashi, JCO); lenvatinib in ACC (Tchekmedyian, JCO)
Trastuzumab Docetaxel Lenvatinib
Sarcomas (2026) · Tazemetostat withdrawn worldwide (9 March); afami-cel full approval and age ≥12 (June); INSIGHT positive
Afamitresgene autoleucel INSIGHT EZH2
Small-cell lung cancer (2026) · Phase 3 readouts pending for I-DXd and tarlatamab maintenance
IDeate-Lung02 DeLLphi-305
Testicular germ cell tumours (2005) · Carboplatin ×1 equals radiotherapy for stage I seminoma (MRC TE19)
Carboplatin
Thymoma and thymic carcinoma (2020) · REMORA: lenvatinib in thymic carcinoma
Lenvatinib
Thyroid cancer (2026) · Selpercatinib label update (July 2026)
Selpercatinib
Triple-negative breast cancer (2026) · Bispecific ADC succeeds; first-line ADC approvals
BL-B01D1-307 Datopotamab deruxtecan Sacituzumab govitecan
Uveal melanoma (2023) · Percutaneous hepatic perfusion (Hepzato) approved
Percutaneous hepatic perfusion (chemosaturation)Melphalan (including hepatic delivery system)
Vulvar cancer (2021) · GOG 279: cisplatin-gemcitabine chemoradiation for locally advanced disease
Cisplatin
Waldenström macroglobulinaemia (2021) · Zanubrutinib approved (ASPEN)
Zanubrutinib
Wilms tumour (2019) · AREN0532: surgery alone confirmed for very-low-risk stage I
Active surveillance

All products approved by 2026 (305)

Radioactive iodine (I-131) 1951 Methotrexate 1953 Cyclophosphamide 1959 Fluorouracil (5-FU) 1962 Vincristine 1963 Dactinomycin (actinomycin D) 1964 Melphalan (including hepatic delivery system) 1964 Vinblastine 1965 Hydroxyurea (hydroxycarbamide) 1967 Cytarabine + anthracycline ('7+3') 1969 Mitotane 1970 Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD) 1971 Bleomycin 1973 Doxorubicin 1974 Mitomycin C 1974 Lomustine (CCNU) 1976 Tamoxifen 1977 Cisplatin 1978 Etoposide 1983 Platinum + etoposide (EP / CE) 1983 Leuprolide (leuprorelin) and GnRH agonists 1985 Interferon alfa-2a/2b 1986 Ifosfamide 1988 Somatostatin analogues (octreotide, lanreotide) 1988 Carboplatin 1989 Goserelin / leuprolide (ovarian function suppression) 1989 Vinorelbine 1989 Intravesical BCG 1990 Aldesleukin (high-dose IL-2) 1992 Paclitaxel / nab-paclitaxel 1992 Cladribine 1993 Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) 1994 Bicalutamide 1995 Tretinoin (all-trans retinoic acid, ATRA) 1995 Gemcitabine 1996 Irinotecan (and liposomal irinotecan) 1996 Oxaliplatin 1996 Topotecan 1996 Letrozole (and other aromatase inhibitors) 1997 Rituximab 1997 Thalidomide 1998 Trastuzumab 1998 Exemestane 1999 Pegylated liposomal doxorubicin 1999 Temozolomide 1999 Arsenic trioxide 2000 Gemtuzumab ozogamicin 2000 Imatinib 2001 Fulvestrant 2002 Bortezomib 2003 Gefitinib 2003 Azacitidine 2004 Bevacizumab 2004 Cetuximab 2004 Docetaxel 2004 Erlotinib 2004 FOLFOX (5-FU, leucovorin, oxaliplatin) 2004 Pemetrexed 2004 Sorafenib 2005 Dasatinib 2006 Lenalidomide 2006 Panitumumab 2006 Sunitinib 2006 5-Aminolevulinic acid (oral, for glioma surgery) 2007 Lapatinib 2007 MammaPrint (70-gene signature) 2007 Nilotinib 2007 Temsirolimus 2007 Trabectedin 2007 Bendamustine 2008 Degarelix 2008 Bevacizumab (glioblastoma use) 2009 Everolimus 2009 Mifamurtide 2009 Pazopanib 2009 Pralatrexate 2009 Romidepsin 2009 Cabazitaxel 2010 Eribulin 2010 Sipuleucel-T 2010 Abiraterone acetate 2011 Brentuximab vedotin 2011 Crizotinib 2011 FOLFIRINOX / mFOLFIRINOX 2011 Ipilimumab 2011 Optune / Optune Pax (TTFields) 2011 Ruxolitinib 2011 Vandetanib 2011 Vemurafenib 2011 Axitinib 2012 Bosutinib 2012 Cabozantinib 2012 Carfilzomib 2012 Enzalutamide 2012 Mogamulizumab 2012 Pertuzumab 2012 Ponatinib 2012 Regorafenib 2012 Vismodegib 2012 Afatinib 2013 Gemcitabine + nab-paclitaxel 2013 Obinutuzumab 2013 Pomalidomide 2013 Radium-223 dichloride 2013 Technetium-99m tilmanocept 2013 Trastuzumab emtansine 2013 Belinostat 2014 Blinatumomab 2014 Ceritinib 2014 Ibrutinib 2014 Idelalisib 2014 Nintedanib 2014 Nivolumab 2014 Nonavalent HPV vaccine 2014 Olaparib 2014 Pembrolizumab 2014 Ramucirumab 2014 Alectinib 2015 Cobimetinib 2015 Daratumumab 2015 Dinutuximab (ch14.18) / dinutuximab beta 2015 Elotuzumab 2015 Ixazomib 2015 Lenvatinib 2015 Osimertinib 2015 Palbociclib 2015 Panobinostat 2015 Sonidegib 2015 Talimogene laherparepvec 2015 Trifluridine/tipiracil 2015 Atezolizumab 2016 Fluciclovine F-18 2016 Gallium-68 DOTATATE (and Cu-64 DOTATATE) 2016 Rucaparib 2016 Venetoclax 2016 Abemaciclib 2017 Acalabrutinib 2017 Avelumab 2017 Axicabtagene ciloleucel 2017 Brigatinib 2017 Copanlisib 2017 CPX-351 (liposomal daunorubicin-cytarabine) 2017 Dabrafenib + trametinib 2017 Enasidenib 2017 FoundationOne CDx / Liquid CDx 2017 Inotuzumab ozogamicin 2017 Midostaurin 2017 Neratinib 2017 Niraparib 2017 Ribociclib 2017 Tisagenlecleucel 2017 Trastuzumab biosimilars 2017 Apalutamide 2018 Binimetinib 2018 Cemiplimab 2018 Dacomitinib 2018 Durvalumab 2018 Duvelisib 2018 Encorafenib 2018 Fruquintinib 2018 Gilteritinib 2018 Glasdegib 2018 Ivosidenib 2018 Larotrectinib 2018 Lorlatinib 2018 Lutetium-177 dotatate 2018 Moxetumomab pasudotox 2018 Pyrotinib 2018 Tagraxofusp 2018 Talazoparib 2018 Toripalimab 2018 Alpelisib 2019 Camrelizumab 2019 Darolutamide 2019 Enfortumab vedotin 2019 Entrectinib 2019 Erdafitinib 2019 Fedratinib 2019 Luspatercept 2019 Pexidartinib 2019 Polatuzumab vedotin 2019 Quizartinib 2019 Ropeginterferon alfa-2b 2019 Selinexor 2019 Tislelizumab 2019 Trastuzumab deruxtecan 2019 Treosulfan 2019 Zanubrutinib 2019 Avapritinib 2020 Belantamab mafodotin 2020 Brexucabtagene autoleucel 2020 Capmatinib & tepotinib 2020 Cetuximab sarotalocan 2020 Decitabine + cedazuridine (oral) 2020 Ensartinib 2020 Fluoroestradiol F-18 (FES PET) 2020 Gallium-68 gozetotide (PSMA-11) 2020 Isatuximab 2020 Lurbinectedin 2020 Margetuximab 2020 Naxitamab 2020 Pemigatinib 2020 Pralsetinib 2020 Relugolix 2020 Ripretinib 2020 Sacituzumab govitecan 2020 Selpercatinib 2020 Tafasitamab 2020 Tazemetostat 2020 Tucatinib 2020 Amivantamab 2021 Asciminib 2021 Belumosudil 2021 Belzutifan 2021 Disitamab vedotin 2021 Dostarlimab 2021 Idecabtagene vicleucel 2021 Lisocabtagene maraleucel 2021 Loncastuximab tesirine 2021 Mobocertinib 2021 Pafolacianine 2021 Penpulimab 2021 Piflufolastat F-18 / Pylarify TruVu 2021 Sotorasib 2021 Tisotumab vedotin 2021 Tivozanib 2021 Umbralisib 2021 Adagrasib 2022 Cadonilimab 2022 Ciltacabtagene autoleucel 2022 Futibatinib 2022 Lutetium-177 vipivotide tetraxetan 2022 Mirvetuximab soravtansine 2022 Mosunetuzumab 2022 Nadofaragene firadenovec 2022 Olutasidenib 2022 Pacritinib 2022 Relatlimab + nivolumab 2022 Serplulimab 2022 Sodium thiosulfate (otoprotectant) 2022 Tebentafusp 2022 Teclistamab 2022 Tremelimumab 2022 Camrelizumab + rivoceranib 2023 Capivasertib 2023 Eflornithine (DFMO) 2023 Elacestrant 2023 Elranatamab 2023 Epcoritamab 2023 Flotufolastat F-18 2023 Glofitamab 2023 Momelotinib 2023 Nirogacestat 2023 Pirtobrutinib 2023 Repotrectinib 2023 Retifanlimab 2023 Sunvozertinib 2023 Talquetamab 2023 Afamitresgene autoleucel 2024 Cosibelimab 2024 Imetelstat 2024 Inavolisib 2024 Ivonescimab 2024 Lazertinib 2024 Lifileucel 2024 NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) 2024 Nogapendekin alfa inbakicept 2024 Obecabtagene autoleucel 2024 Odronextamab 2024 Pegulicianine 2024 Revumenib 2024 Sacituzumab tirumotecan 2024 Shield 2024 Tarlatamab 2024 Tovorafenib 2024 Vorasidenib 2024 Zanidatamab 2024 Zenocutuzumab 2024 Zolbetuximab 2024 ArteraAI Prostate 2025 Avutometinib + defactinib 2025 Datopotamab deruxtecan 2025 Dordaviprone 2025 Gemcitabine intravesical system (TAR-200) 2025 Imlunestrant 2025 Linvoseltamab 2025 Satricabtagene autoleucel 2025 Sevabertinib 2025 Sonrotoclax 2025 Taletrectinib 2025 Telisotuzumab vedotin 2025 Trastuzumab rezetecan 2025 Vimseltinib 2025 Ziftomenib 2025 Zongertinib 2025 ArteraAI Breast 2026 Camizestrant 2026 Daraxonrasib 2026 Gedatolisib 2026 Pivekimab sunirine 2026 Relacorilant 2026 Rusfertide 2026 Vepdegestrant 2026 Vusolimogene oderparepvec 2026 Zidesamtinib 2026